(Q40240958)

English

Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer

scientific article published on 14 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Khursheed Anwer

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

F Joseph Kelly

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Christina Chu

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Jason G Fewell

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Danny Lewis

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Ronald D Alvarez

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

14 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

131

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

169-173

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Latest research and treatment of advanced-stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Novel therapies for recurrent ovarian cancer management

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Interleukin-12-mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Treatment of SCCVII tumors with systemic chemotherapy and Interleukin-12 gene therapy combination

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Cytokine-release syndrome: overview and nursing implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.081

7 January 2021

Identifiers

10.1016/J.YGYNO.2013.07.081

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40240958&oldid=1889783910"